SLC5A2 and chronic kidney disease: Sodium glucose co-transporter 2 (SGLT2) inhibitors are the antidiabetic agents of choice, along with glucagon-like peptide 1 receptor agonists, in patients with type 2 diabetes mellitus (T2DM) who also have established atherosclerotic cardiovascular disease (CVD), are at high risk for CVD, have established heart failure (HF) and/or have chronic kidney disease (CKD) [1,2].